Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting

KB-0742 demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors  

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the presentation of positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting in Dublin, Ireland. Today’s presentation by Dr. Van Tine of Washington University School of Medicine includes clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Massachusetts in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity. Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.

“Sarcomas are very complex to diagnose and treat so there is a significant need for innovation in this field,” said Brian Van Tine, M.D., of Washington University School of Medicine in St. Louis. “I am very encouraged by the positive preliminary KB-0742 data, not only for what it could mean for sarcoma patients, but also for other cancer types given evidence of on-mechanism clinical activity and a manageable safety profile. Today, I shared a case study on one of my sarcoma patients who exhausted all standard therapies as well as multiple experimental treatments. This patient received KB-0742 for more than a year and experienced objective clinical benefit, including the shrinkage of their tumor. I look forward to learning more about the utility of KB-0742 from the ongoing dose escalation and expansion studies.”